Mizuho analyst Difei Yang raised her price target for Avrobio to $35 from $28 citing positive clinical data updates yesterday at WORLDSymposium 2020. The company's clinical data in fabry disease continues to support a potential best-in-class gene therapy, and transition from academic process to the company's proprietary platform could offer additional clinical benefits, Yang tells investors in a research note. Further, its initial data in cystinosis was also positive, adds the analyst. She believes multiple data updates throughout 2020 could provide further upside to Avrobio shares. Yang reiterates a Buy rating on the name.